JP2012532619A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532619A5
JP2012532619A5 JP2012520015A JP2012520015A JP2012532619A5 JP 2012532619 A5 JP2012532619 A5 JP 2012532619A5 JP 2012520015 A JP2012520015 A JP 2012520015A JP 2012520015 A JP2012520015 A JP 2012520015A JP 2012532619 A5 JP2012532619 A5 JP 2012532619A5
Authority
JP
Japan
Prior art keywords
dom1h
tnfr1
antagonist
tnfα
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012520015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532619A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/060111 external-priority patent/WO2011006914A2/en
Publication of JP2012532619A publication Critical patent/JP2012532619A/ja
Publication of JP2012532619A5 publication Critical patent/JP2012532619A5/ja
Pending legal-status Critical Current

Links

JP2012520015A 2009-07-16 2010-07-14 Tnfr1を部分的に阻害するためのアンタゴニスト、用途および方法 Pending JP2012532619A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22609409P 2009-07-16 2009-07-16
US61/226,094 2009-07-16
PCT/EP2010/060111 WO2011006914A2 (en) 2009-07-16 2010-07-14 Antagonists, uses & methods for partially inhibiting tnfr1

Publications (2)

Publication Number Publication Date
JP2012532619A JP2012532619A (ja) 2012-12-20
JP2012532619A5 true JP2012532619A5 (cg-RX-API-DMAC7.html) 2013-08-29

Family

ID=43304850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520015A Pending JP2012532619A (ja) 2009-07-16 2010-07-14 Tnfr1を部分的に阻害するためのアンタゴニスト、用途および方法

Country Status (5)

Country Link
US (1) US20120107330A1 (cg-RX-API-DMAC7.html)
EP (1) EP2453920A2 (cg-RX-API-DMAC7.html)
JP (1) JP2012532619A (cg-RX-API-DMAC7.html)
CA (1) CA2768460A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011006914A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075505A1 (es) * 2009-02-19 2011-04-06 Glaxo Group Ltd Variantes de union a anti- albumina de suero mejoradas
AU2010215479B2 (en) * 2009-02-19 2015-01-22 Glaxo Group Limited Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
WO2011008814A2 (en) * 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Multiplexed measurement of exogenous and endogenous dna
KR20130109977A (ko) * 2010-05-20 2013-10-08 글락소 그룹 리미티드 개선된 항-혈청 알부민 결합 변이체
WO2015104322A1 (en) 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
CA2950299A1 (en) 2014-06-02 2015-12-10 Li-Cor, Inc. Phthalocyanine probes and uses thereof
US11701391B2 (en) 2017-10-24 2023-07-18 Dalia ELANI Methods of treating an ischemic disease
US12472266B2 (en) 2019-02-21 2025-11-18 Enosi Therapeutics Corporation Antibodies and enonomers
US20220288226A1 (en) * 2020-08-27 2022-09-15 Enosi Life Sciences Corp. Methods and compositions to treat autoimmune diseases and cancer
IL300930A (en) 2020-08-27 2023-04-01 Enosi Therapeutics Corp Methods and compositions for the treatment of autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
MX2023015434A (es) * 2021-06-17 2024-04-29 Immunicom Inc Tnf modificado como un ligando de captura.
CN114699533B (zh) * 2022-05-06 2023-05-09 郑州大学 一种核酸适配体和多肽交联的双靶点复合核酸纳米药物制备方法与应用
WO2024165823A2 (fr) 2023-02-09 2024-08-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA94040A (en) 1904-09-04 1905-07-04 Emile Leo Behrmann Machine for making boxes or wrappers
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル. モリソン,シェリー ドメイン‐変性不変部を有する抗体
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
EP1908832B1 (en) 1997-07-07 2012-12-26 Medical Research Council A method for increasing the concentration of a nucleic acid molecule
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
AU2004239065B2 (en) 2003-05-14 2008-05-15 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
EP1737962B1 (en) 2004-03-24 2010-09-01 Domantis Limited Gas1 universal leader
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
CN101111522A (zh) 2004-12-02 2008-01-23 杜门蒂斯有限公司 由于和功能域抗体缀合而具有提高的血清半衰期的plad功能域肽
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
FR2903032B1 (fr) 2006-06-29 2008-10-17 Ecole Polytechnique Etablissem "procede et dispositif d'usinage d'une cible par faisceau laser femtoseconde."
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
AU2010215479B2 (en) * 2009-02-19 2015-01-22 Glaxo Group Limited Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists

Similar Documents

Publication Publication Date Title
JP2012532619A5 (cg-RX-API-DMAC7.html)
JP2012517818A5 (cg-RX-API-DMAC7.html)
Wendt et al. CCR9 antagonism: potential in the treatment of inflammatory bowel disease
JP2019504086A5 (cg-RX-API-DMAC7.html)
JP2012021001A5 (cg-RX-API-DMAC7.html)
JP2014503482A5 (cg-RX-API-DMAC7.html)
ES2895552T3 (es) Anticuerpo
JP2016512248A5 (cg-RX-API-DMAC7.html)
JP2017029157A5 (cg-RX-API-DMAC7.html)
JP2016041733A5 (cg-RX-API-DMAC7.html)
JP2014169326A5 (cg-RX-API-DMAC7.html)
JP2010524489A5 (cg-RX-API-DMAC7.html)
JP2009521398A5 (cg-RX-API-DMAC7.html)
JP2015522252A5 (cg-RX-API-DMAC7.html)
JP2019510739A5 (cg-RX-API-DMAC7.html)
US20160333103A1 (en) Baff selective binding compounds and related methods
JP2019521647A5 (cg-RX-API-DMAC7.html)
JP2012509269A5 (cg-RX-API-DMAC7.html)
JP2020531030A5 (cg-RX-API-DMAC7.html)
JP2017523776A5 (cg-RX-API-DMAC7.html)
JP2020510000A5 (cg-RX-API-DMAC7.html)
JP2014516924A5 (cg-RX-API-DMAC7.html)
JP2017530372A5 (cg-RX-API-DMAC7.html)
JP2009215293A5 (cg-RX-API-DMAC7.html)
JP2019528285A5 (cg-RX-API-DMAC7.html)